Cargando…
Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019
Background: Yindan Jiedu Granules (YDJDG) have been newly prescribed as a Chinese herbal formula. This study aimed to compare the efficacy of YDJDG and lopinavir-ritonavir in the treatment of coronavirus disease 2019 (COVID-19). Methods: Overall, 131 patients with COVID-19 were included in this stud...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957926/ https://www.ncbi.nlm.nih.gov/pubmed/33732148 http://dx.doi.org/10.3389/fphar.2020.634266 |
_version_ | 1783664755955728384 |
---|---|
author | Liu, Jingyuan Jiang, Yuyong Liu, Yao Pu, Lin Du, Chunjing Li, Yuxin Wang, Xiaojing Ren, Jie Liu, Wei Yang, Zhiyun Chen, Zhihai Song, Rui Xie, Wen Wang, Xianbo |
author_facet | Liu, Jingyuan Jiang, Yuyong Liu, Yao Pu, Lin Du, Chunjing Li, Yuxin Wang, Xiaojing Ren, Jie Liu, Wei Yang, Zhiyun Chen, Zhihai Song, Rui Xie, Wen Wang, Xianbo |
author_sort | Liu, Jingyuan |
collection | PubMed |
description | Background: Yindan Jiedu Granules (YDJDG) have been newly prescribed as a Chinese herbal formula. This study aimed to compare the efficacy of YDJDG and lopinavir-ritonavir in the treatment of coronavirus disease 2019 (COVID-19). Methods: Overall, 131 patients with COVID-19 were included in this study. In addition to standard care, 60 of these patients received YDJDG (YDJDG group) and 71 received lopinavir-ritonavir (lopinavir-ritonavir group). Propensity score matching (PSM) was used to match the characteristics of individuals in the two groups, while the Kaplan-Meier method was used to compare the proportion recovery observed. Results: Cox analysis revealed that YDJDG and CD4 ≥ 660 cells/µL were independent predictive factors of proportion recovery. At baseline, disease types differed between the YDJDG and lopinavir-ritonavir treatment groups. Furthermore, no significant adverse effects or toxicities relevant to YDJDG were observed. The median recovery time was 21 days in the YDJDG group and 27 days in the lopinavir-ritonavir group. After PSM (1:1), 50 patient pairs, YDJDG vs. lopinavir-ritonavir, were analyzed. In the YDJDG group, the proportion of recovered patients was remarkably higher than that observed in the lopinavir-ritonavir group (p = 0.0013), especially for those presenting mild/moderate disease type and CD4 < 660 cells/µL. In the YDJDG group, the mean duration of fever and pulmonary exudative lesions was significantly shorter than that observed in the lopinavir-ritonavir group (p = 0.0180 and p = 0.0028, respectively). Conclusion: YDJDG reveals the potential to hasten the recovery period in COVID-19 patients with mild/moderate disease type or CD4 < 660 cells/µL by shortening the mean duration of fever and pulmonary exudative lesions. |
format | Online Article Text |
id | pubmed-7957926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79579262021-03-16 Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 Liu, Jingyuan Jiang, Yuyong Liu, Yao Pu, Lin Du, Chunjing Li, Yuxin Wang, Xiaojing Ren, Jie Liu, Wei Yang, Zhiyun Chen, Zhihai Song, Rui Xie, Wen Wang, Xianbo Front Pharmacol Pharmacology Background: Yindan Jiedu Granules (YDJDG) have been newly prescribed as a Chinese herbal formula. This study aimed to compare the efficacy of YDJDG and lopinavir-ritonavir in the treatment of coronavirus disease 2019 (COVID-19). Methods: Overall, 131 patients with COVID-19 were included in this study. In addition to standard care, 60 of these patients received YDJDG (YDJDG group) and 71 received lopinavir-ritonavir (lopinavir-ritonavir group). Propensity score matching (PSM) was used to match the characteristics of individuals in the two groups, while the Kaplan-Meier method was used to compare the proportion recovery observed. Results: Cox analysis revealed that YDJDG and CD4 ≥ 660 cells/µL were independent predictive factors of proportion recovery. At baseline, disease types differed between the YDJDG and lopinavir-ritonavir treatment groups. Furthermore, no significant adverse effects or toxicities relevant to YDJDG were observed. The median recovery time was 21 days in the YDJDG group and 27 days in the lopinavir-ritonavir group. After PSM (1:1), 50 patient pairs, YDJDG vs. lopinavir-ritonavir, were analyzed. In the YDJDG group, the proportion of recovered patients was remarkably higher than that observed in the lopinavir-ritonavir group (p = 0.0013), especially for those presenting mild/moderate disease type and CD4 < 660 cells/µL. In the YDJDG group, the mean duration of fever and pulmonary exudative lesions was significantly shorter than that observed in the lopinavir-ritonavir group (p = 0.0180 and p = 0.0028, respectively). Conclusion: YDJDG reveals the potential to hasten the recovery period in COVID-19 patients with mild/moderate disease type or CD4 < 660 cells/µL by shortening the mean duration of fever and pulmonary exudative lesions. Frontiers Media S.A. 2021-02-05 /pmc/articles/PMC7957926/ /pubmed/33732148 http://dx.doi.org/10.3389/fphar.2020.634266 Text en Copyright © 2021 Liu, Jiang, Liu, Pu, Du, Li, Wang, Ren, Liu, Yang, Chen, Song, Xie and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Liu, Jingyuan Jiang, Yuyong Liu, Yao Pu, Lin Du, Chunjing Li, Yuxin Wang, Xiaojing Ren, Jie Liu, Wei Yang, Zhiyun Chen, Zhihai Song, Rui Xie, Wen Wang, Xianbo Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
title | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
title_full | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
title_fullStr | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
title_full_unstemmed | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
title_short | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
title_sort | yindan jiedu granules, a traditional chinese medicinal formulation, as a potential treatment for coronavirus disease 2019 |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957926/ https://www.ncbi.nlm.nih.gov/pubmed/33732148 http://dx.doi.org/10.3389/fphar.2020.634266 |
work_keys_str_mv | AT liujingyuan yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT jiangyuyong yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT liuyao yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT pulin yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT duchunjing yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT liyuxin yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT wangxiaojing yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT renjie yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT liuwei yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT yangzhiyun yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT chenzhihai yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT songrui yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT xiewen yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT wangxianbo yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 |